Oral lichen planus
Drug research and approvals for oral lichen planus: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 15 studies of oral lichen planus are recruiting on ClinicalTrials.gov, and Health Canada has authorized 2 drug trials for it since 2013.
- Recruiting worldwide: 15
- Trials authorized in Canada: 2
- FDA orphan approvals: 0
- EU medicines: 0
- Study of Modzatinib (ATI-2138) in Adult Participants With Biopsy-proven Forms of Lichen Planus Not Adequately…NCT07935590 · Phase 2 · Aclaris Therapeutics, Inc. · starts Nov 1, 2026
- Salivary IL-8 and Serum IL-6 as Biomarkers for Oral Potentially Malignant Disorders in Smokers and Never-SmokersNCT07915570 · Not reported · British University In Egypt · starts Oct 1, 2026
- Observational Study of OROSEDAL in Sore Throat and Minor Oral LesionsNCT07620353 · Not reported · Laboratoires Elerte · starts Mar 5, 2026
- A Phase 2/3 Study of Brepocitinib in Adults With Lichen PlanopilarisNCT07532603 · Phase 2 / Phase 3 · Priovant Therapeutics, Inc. · starts Mar 19, 2026
- Photobiomodulation, Photodynamic Therapy, and Clobetasol in the Treatment of Oral Lichen Planus.NCT07278999 · Not applicable · Medical University of Silesia · starts Dec 1, 2025
- Evaluation of Efficacy and Safety of add-on Tofacitinib in Patients With Oral Lichen PlanusNCT07131813 · Phase 4 · All India Institute of Medical Sciences, Bhubaneswar · starts Oct 10, 2025
- Mucoadhesive Modified-Release Formulations for the Topical Treatment of Symptomatic Oral Lichen PlanusNCT07100613 · Phase 2 · University of Palermo · starts Sep 4, 2024
- Effect of Topical Bromelain Versus Topical Corticosteroids in the Management of Oral Lichen PlanusNCT06981767 · Phase 2 · Cairo University · starts Feb 18, 2026
- Rate of Malignant Transformation and Clinical Characteristics Among an Oral Lichen Planus Cohort: a Retrospective…NCT06934863 · Not reported · Catholic University of the Sacred Heart · starts Jan 31, 2024
Phase 3 6
- Triamcinolone acetonideGlucocorticoid receptor agonist
- DexamethasoneGlucocorticoid receptor agonist
- SirolimusFK506-binding protein 1A inhibitor
- MinocyclineBacterial 70S ribosome inhibitor
- Epoetin betaErythropoietin receptor agonist
- Epigalocatechin gallate
Phase 2 12 of 14
- Clobetasol propionateGlucocorticoid receptor agonist
- TriamcinoloneGlucocorticoid receptor agonist
- PimecrolimusFK506-binding protein 1A inhibitor
- Curcumin
- Clobetasol
- DoxycyclineMatrix metalloproteinase 7 inhibitor
- MetronidazoleDNA inhibitor
- TacrolimusFK506-binding protein 1A inhibitor
- PrednisoneGlucocorticoid receptor agonist
- Betamethasone dipropionateGlucocorticoid receptor agonist
- Omega-3-ACID ethyl esters
- ApremilastPhosphodiesterase 4 inhibitor
Phase 1 or earlier 5
How its trials ended
120 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 16 whose ending is known, 69% met their primary endpoint, 0% missed it and 31% stopped early.
- Completed, result not reported6050%
- Ongoing2319%
- Status unknown2118%
- Met its primary endpoint119%
- Stopped: enrollment or feasibility22%
- Stopped: other or unclear22%
- Stopped: funding11%
| Jul 18, 2018 | The apolp trial: a single-center, randomized, 16 weeks, explanatory, parallel group, superiority, blinded, placebo-controlled, clinical trial of apremilast use…Apremilast | Sunnybrook Research Institute | Ongoing |
| Jul 10, 2018 | A randomized, double-blind, placebo-controlled, parallel group clinical study to assess the safety and efficacy of three doses of clobetasol propionate when…Clobetasol | Afyx Therapeutics A/S | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA